Shares of Gilead Sciences Inc. GILD slid 3.09% to $103.25 Thursday, on what proved to be an all-around favorable trading ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

Shares of Gilead Sciences Inc. GILD rallied 2.24% to $106.54 Wednesday, on what proved to be an all-around favorable trading ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

[CNBC] Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Gilead Sciences to Pay $202 Million in US Settlement Over HIV Drug Kickbacks By Jonathan Stempel NEW YORK (Reuters) -Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit ...